Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-99
SponsorNovartis Pharmaceuticals
About this trial
This study has the purpose to answer how the Lipoprotein(a) (Lp(a)) level is distributed among Atherosclerotic cardiovascular disease (ASCVD) patients in Russia, and what is the connection between elevated levels of this parameter and the cardiovascular disease (CVD) risk.
Eligibility criteria
Qualifiers
Written informed consent (signed and dated).
Males and females aged ≥18 years.
history of MI;
history of IS and/or TIA;
Disqualifiers
Acute infectious and inflammatory diseases, such as COVID-19, in the month leading up to the Screening visit.
Lp(a)-lowering therapy/methods (Lp(a) apheresis with PCSK9 inhibitors, inclisiran prior to the Screening visit) in the medical history before the Screening visit.
Participation in any interventional clinical study with investigational or marketed medicinal products at the time of enrollment.
Participation in other real-world clinical studies.
Trial design
Treatments tested in this trial
- Atorvastatin
- Simvastatin
- Rozuvastatin
- Ezetimibe
- Niacin
- Ciprofibrate
- Fenofibrate
- Bezafibrate
- Evolocumab
- Alirocumab
- Inclisiran
Treatment groups
2,382 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov